Thyroid Cancer - Therapeutics Assessment Pipeline Review, H1 2014 adds “Thyroid Cancer – Pipeline Review, H1 2014” to its store. The report provides an overview of the Thyroid Cancer’s therapeutic pipeline.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

This report provides comprehensive information on the therapeutic development for Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thyroid Cancer and special features on late-stage and discontinued projects.

Complete report available @ .


  • The report provides a snapshot of the global therapeutic landscape of Thyroid Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Thyroid Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Thyroid Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Thyroid Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Thyroid Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Thyroid Cancer Overview 8
Therapeutics Development 9
Pipeline Products for Thyroid Cancer - Overview 9
Pipeline Products for Thyroid Cancer - Comparative Analysis 10
Thyroid Cancer - Therapeutics under Development by Companies 11
Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes 13
Thyroid Cancer - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Thyroid Cancer - Products under Development by Companies 17
Thyroid Cancer - Products under Investigation by Universities/Institutes 18
Thyroid Cancer - Companies Involved in Therapeutics Development 19
AstraZeneca PLC 19
GlaxoSmithKline plc 20
Takeda Pharmaceutical Company Limited 21
Bio-Path Holdings, Inc. 22
Novartis AG 23
Eisai Co., Ltd. 24
Bionomics Limited 25
Azaya Therapeutics Incorporated 26
Vascular Biogenics Ltd. 27
Biovista Inc. 28
Trophogen, Inc. 29
centrose llc 30
Ecrins Therapeutics SAS 31
Thyroid Cancer - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 37
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
lenvatinib - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
vandetanib - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
selumetinib sulfate - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
motesanib diphosphate - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
everolimus - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
VB-111 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
dabrafenib - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
pazopanib hydrochloride - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
docetaxel liposomal - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
GSK-2256098 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Recombinant Adenoviral Human p53 Gene Therapy - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
BP-100-1.02 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
TRX-201 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
ETD-5 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Vascular Endothelial Growth Factor Superagonist - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
TR-1401 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Drug Adaptation Program - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
EDC-1 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
BVA-501 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
BVA-701 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Drug For Lung and Thyroid Cancer - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Small Molecules to Inhibit PAK for Thyroid Cancer - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Thyroid Cancer - Recent Pipeline Updates 87
Thyroid Cancer - Dormant Projects 108
Thyroid Cancer - Discontinued Products 109
Thyroid Cancer - Product Development Milestones 110
Featured News & Press Releases 110
Jun 20, 2014: Bayer Receives Approval for Nexavar (sorafenib) in Japan for Treatment of Differentiated Thyroid Cancer 110
May 31, 2014: Lenvatinib Phase III Results Show Significant Improvement In Progression-Free Survival In Patients With Radioiodine-Refractory Differentiated Thyroid Cancer 111
May 30, 2014: Bayer Receives EU Approval for Nexavar (sorafenib) for the Treatment of Differentiated Thyroid Cancer 111
May 15, 2014: Eisai to Present Abstracts On Lenvatinib At 50th ASCO Annual Meeting 112
May 14, 2014: Cabozantinib and Cobimetinib to Be Featured in Ten Presentations at 2014 ASCO Annual Meeting 113
Apr 25, 2014: European Medicines Agency recommends extending use of Nexavar to include treatment of differentiated thyroid cancer 115
Apr 23, 2014: Phase 3 DECISION Trial of NEXAVAR (sorafenib) in Locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Cancer Refractory to Radioactive Iodine Published in The Lancet 116
Mar 25, 2014: Cometriq approved in Europe for the treatment of progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma 116
Feb 03, 2014: Phase III Trial Shows Lenvatinib Meets Primary Endpoint Of Progression Free Survival Benefit in Treatment Of Radioiodine-refractory Differentiated Thyroid Cancer 117
Nov 22, 2013: Nexavar Receives Approval for the Treatment of Differentiated Thyroid Cancer in the U.S. 118
Appendix 120
Methodology 120
Coverage 120
Secondary Research 120
Primary Research 120
Expert Panel Validation 120
Contact Us 121
Disclaimer 121

Browse more reports on Cancer Drugs Market @ .

About Us: is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.